Basidiolipids from Agaricus are novel immune adjuvants.
The primary aim of the present study was to compare the immune adjuvanticity of two different groups of glycolipids, i.e., the newly discovered basidiolipids from Basidiomycete mushrooms (Bl-1, Bl-2, Bl-3, and Bl-4), and saponin fractions from Quillaja saponaria. The basidiolipids, though with differential effectiveness of the Bl-components, stimulated the expression of serum immune globulins in mice that recognized co-injected antigens, bovine serum albumin (BSA) or a keyhole-limpet hemocyanin-ganglioside Gfpt1 conjugate (KLH-Gfpt1), respectively. The immune adjuvanticity of the basidiolipids was comparable to that of acidic (QAS2, QAS5, QAS10), and novel neutral (QNS1, QNS2, QNS3) saponin compounds isolated and purified from Quillaja saponaria bark bulk material. Basidiolipids, as well as, the Q. saponin fractions were only marginally antigenic. MPL-A, by contrast, a comparable immune adjuvant, stimulated the expression of specific antibodies that recognized this glycophospholipid. Different from the Q. saponins with restricted toxicity, the basidiolipids displayed no toxic or hemolytic properties.
Jennemann
R
R
Zentrum für Operative Medizin I, Philipps-Universität-Marburg, Germany.
Bauer
B L
BL
Bertalanffy
H
H
Selmer
T
T
Wiegandt
H
H
D000276:Adjuvants, Immunologic; D000364:Agaricus / Q000276:immunology*; D000818:Animals; D002417:Cattle; D005260:Female; D006017:Glycolipids / Q000276:immunology*; D006461:Hemolysis; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D012503:Saponins / Q000276:immunology
D000276:Adjuvants, Immunologic; D006017:Glycolipids; D012503:Saponins